{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045283","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.253608+00:00","generated_at":"2026-05-30T00:20:55.344104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M","bullets":["GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.","VEVYE prescriptions up 55% QoQ; IHEEZO unit demand up 15% QoQ; TRIESENCE relaunched in October.","Cash $72.6M; $37M milestone payment for TRIESENCE funded by $30M Oaktree drawdown.","First major Medicare Part D win for VEVYE with Express Scripts, Cigna, Kaiser, CVS Caremark.","FY2024 revenue guidance reaffirmed at >$180M; Q4 expected to significantly outpace Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045283","json":"https://secwatch.observer/filing/0001493152-24-045283.json","markdown":"https://secwatch.observer/filing/0001493152-24-045283.md","text":"https://secwatch.observer/filing/0001493152-24-045283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/0001493152-24-045283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:20:55.344104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}